R&D News | pharmaphorum

News

UK psychiatrists have called for a relaxation of restrictive rules on testing psychedelics, which are holding back research and clinical use.

News

There is only one approved drug for ultra-rare disease FOP on the market, but Regeneron is hoping to add a second.

News

Novo Nordisk has trumpeted data showing oral Wegovy matched the injectable version in a phase 3 trial, ramping up pressure on rival Eli Lilly.

News

Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its phase 3 candidate pegozafermin for MASH.

News

Eli Lilly is preparing to file for approval of its oral weight-loss drug orforglipron before year-end, but not all are convinced by the data.

News

GSK's investment drive includes a new facility in Pennsylvania, and follows some high-profile abandoned projects by drugmakers in the UK.